Headlands Technologies LLC Makes New $613,000 Investment in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Headlands Technologies LLC bought a new stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 276,260 shares of the biopharmaceutical company’s stock, valued at approximately $613,000. Headlands Technologies LLC owned 0.15% of Esperion Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of ESPR. CVI Holdings LLC bought a new stake in Esperion Therapeutics during the first quarter worth about $37,000. Simplicity Wealth LLC acquired a new position in shares of Esperion Therapeutics in the 1st quarter valued at approximately $44,000. Sivia Capital Partners LLC bought a new stake in shares of Esperion Therapeutics during the 2nd quarter worth approximately $44,000. National Bank of Canada FI boosted its position in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,225 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System bought a new position in Esperion Therapeutics in the first quarter valued at approximately $50,000. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Stock Performance

Shares of ESPR opened at $1.74 on Thursday. Esperion Therapeutics, Inc. has a 52 week low of $0.70 and a 52 week high of $3.40. The stock has a market capitalization of $329.66 million, a price-to-earnings ratio of -1.76 and a beta of 1.00. The stock has a fifty day moving average of $2.10 and a 200-day moving average of $2.27.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.10. The firm had revenue of $73.83 million during the quarter, compared to the consensus estimate of $51.90 million. As a group, equities analysts forecast that Esperion Therapeutics, Inc. will post -0.04 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research note on Monday, August 12th. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Needham & Company LLC decreased their target price on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. Finally, Bank of America cut shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and dropped their target price for the stock from $2.90 to $2.50 in a report on Thursday, June 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $8.17.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.